Oct Angiography Changes After Local Anesthesia in Cataract Surgery

OCT Angiography Changes of Retinal Microvasculature After Local Anesthesia in Cases Undergoing Cataract Surgery

Assessement of retinal microvasculature detected by OCT-angio after peribulbar &retrobulbar anesthesia in cases undergoing cataract surgery .

Study Overview

• Status: Not yet recruiting
• Conditions: OCTA Changes With Local Anesthesia
• Intervention / Treatment: Drug: Local Anesthesia (peribular injection of both lidocaine 2 % and hyaluronidase 150IU\ML); Drug: Local Anesthesia (peribulbar anesthesia injection of mepivacaine 2% and hyaluronidase 150IU\ML); Drug: Local Anesthesia (retrobulbar anesthesia injection of lidocaine 2 % and hyaluronidase 150IU\ML); Drug: local Anesthesia (retrobulbar anesthesia injection of mepivacaine 2% and hyaluronidase 150IU\ML)

Detailed Description

prospective , interventional,comparative , clinical study utilizing a pre-post, within-subject design ,which will be conducted in the Department of Ophthalmology ,Sohag University Hospital ,Egypt.

Optical coherence tomography angiography (OCTA) will be performed before and after the administration of retrobulbar and peribulbar local anesthesia in the same cohort of patients, in order to evaluate the immediate effects of the anesthetic intervention on retinal microvascular parameters.the study will be conducted on patients aged 40-80 years with elective cataract surgery requiring regional block.the study will be divided into two main groups :

1. Group with peribulbar anesthesia injection.
2. Group with retrobulbar anesthesia injection.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Amira aldesoky abdelazeem ahmed, resident; Phone Number: 01055330581; Email: amera.desouky@med.sohag.edu.eg
• Study Contact Backup: Name: Mohamed Anber Abdellatif, professor; Phone Number: 01009801966

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. patients aged 40-80 years.
2. patients with elective cataract surgery requiring regional block.

Exclusion Criteria:

• 1.Allergy to study drugs. 2. Media opacities affecting OCT imaging (corneal pathologies, dense cataracts, vitreous.

opacities, etc). 3. Patients with any other retinal vascular diseases (retinal vein occlusion, central serous chorioretinopathy, age-related macular degeneration, etc).

4. Patients who have had previous intravitreal injections or Laser treatment. 5. Patients who underwent previous vitreoretinal surgeries. 6. Patients with uncontrolled glaucoma or ocular inflammations (eg: vitritis). 7.Patients with diabetes mellitus or hypertension.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: group A; peribulbar anesthesia injection of two anesthetic agents ( lidocaine 2 %+ hyaluronidase 150IU\ML )	Drug: Local Anesthesia (peribular injection of both lidocaine 2 % and hyaluronidase 150IU\ML); peribular injection of both lidocaine 2 % and hyaluronidase 150IU\ML
Active Comparator: group A1; peribulbar anesthesia injection ( mepivacaine 2% + hyaluronidase 150IU\ML )	Drug: Local Anesthesia (peribulbar anesthesia injection of mepivacaine 2% and hyaluronidase 150IU\ML); peribulbar anesthesia injection of mepivacaine 2% and hyaluronidase 150IU\ML
Active Comparator: group B; retrobulbar anesthesia injection ( lidocaine 2 %+ hyaluronidase 150IU\ML )	Drug: Local Anesthesia (retrobulbar anesthesia injection of lidocaine 2 % and hyaluronidase 150IU\ML); retrobulbar anesthesia injection of lidocaine 2 % and hyaluronidase 150IU\ML
Active Comparator: group B1; retrobulbar anesthesia injection ( mepivacaine 2% + hyaluronidase 150IU\ML )	Drug: local Anesthesia (retrobulbar anesthesia injection of mepivacaine 2% and hyaluronidase 150IU\ML); retrobulbar anesthesia injection of mepivacaine 2% and hyaluronidase 150IU\ML

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Macular superficial capillary plexus (SCP) and deep capillary plexus (DCP	to detect degree of changes in vessel density at superficial and deep macular plexuses before and after injection of each group of anesthesia	ntervention & data collection :4-6 monthes

Collaborators and Investigators

• Sponsor: Sohag University

Publications and helpful links

General Publications

• Rao HL, Pradhan ZS, Suh MH, Moghimi S, Mansouri K, Weinreb RN. Optical Coherence Tomography Angiography in Glaucoma. J Glaucoma. 2020 Apr;29(4):312-321. doi: 10.1097/IJG.0000000000001463.
• Ali H, Eissa S, Magdy H, Khashba M. Dexmedetomidine as an Additive to Local Anesthesia for Decreasing Intraocular Pressure in Glaucoma Surgery: A Randomized Trial. Anesth Pain Med. 2020 Jun 27;10(3):e100673. doi: 10.5812/aapm.100673. eCollection 2020 Jun.
• Kalra G, Zarranz-Ventura J, Chahal R, Bernal-Morales C, Lupidi M, Chhablani J. Optical coherence tomography (OCT) angiolytics: a review of OCT angiography quantitative biomarkers. Surv Ophthalmol. 2022 Jul-Aug;67(4):1118-1134. doi: 10.1016/j.survophthal.2021.11.002. Epub 2021 Nov 5.

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): March 1, 2027

Study Registration Dates

• First Submitted: December 9, 2025
• First Submitted That Met QC Criteria: December 9, 2025
• First Posted (Actual): December 23, 2025

Study Record Updates

• Last Update Posted (Actual): December 23, 2025
• Last Update Submitted That Met QC Criteria: December 9, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: OCTA , local anesthesia
• Additional Relevant MeSH Terms: Anesthesia and Analgesia; Anesthesia, Conduction; Anesthesia; Anesthesia, Local
• Other Study ID Numbers: Soh-Med-25-9-22MS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No